The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Guidelines for Acromegaly Management
Open accessAbstract
In May 2000, an Acromegaly Treatment Workshop was held to develop a consensus statement reflecting the integrated opinions of 68 leading neuroendocrinologists and neurosurgeons worldwide. Acromegaly is an insidious disorder caused by a pituitary GH-secreting adenoma resulting in high circulating levels of GH and IGF-I (1). Unfortunately, no single therapy is comprehensively successful in controlling the disease and its protean clinical manifestations, and different treatment modes are associated with unique adverse effects and clinical disadvantages (2). Surgery, radiation, and medical treatments are available for lowering GH and IGF-I hypersecretion, controlling pituitary tumor mass effects, and improving morbidity (3). Recent studies provide a compelling rationale for controlling GH and IGF-I secretion as being the most significant determinant of restoring the observed adverse mortality to control rates (4–6). Regardless of the therapeutic mode, the goal of treatment is to control GH levels to less than 1 μg/liter after an oral glucose load (Fig. 1), normalize age- and gender-matched IGF-I levels, ablate or reduce tumor mass and prevent its recurrence, and alleviate significant comorbid features, especially cardiovascular, pulmonary, and metabolic derangements (7, 8). Control implies GH less than 1 ng/ml after an oral glucose load and normalized age- and gender-matched IGF-I levels. DXRT, Radiation therapy. Transsphenoidal surgery is the procedure of choice for the initial management of acromegaly, and craniotomy is very rarely indicated (4, 5, 9–12). Uniform biochemical and local anatomic outcome criteria should be applied in determining success for all acromegaly treatments. Complete microadenoma resection and maximal removal of locally impinging tumor and hyperfunctioning macroadenomas are desired anatomic outcomes. Reoperation for surgically accessible residual or recurrent tumor remnants visualized by magnetic resonance imaging (MRI) should be considered in patients who fail to achieve surgical remission as defined by rigorous biochemical criteria. Somatostatin receptor ligand (SRL) pretreatment of patients destined for surgery may be useful in patients with serious medical complications of acromegaly (13), but no data are available on influencing surgical outcomes. Technical surgical adjuncts such as endoscopy, neuronavigation, intraoperative hormone assays, and intraoperative MRI may improve operative outcome, patient satisfaction, and complication rates, but definitive data on the impact of these procedures on surgical outcomes are not yet available. Early GH assessment after surgery is useful, and oral glucose tolerance testing and IGF-I assessment should be performed within 2–4 months after surgery and interpreted according to established criteria for defining disease control (8, 14). The results of pituitary surgery are optimal when performed in specialized centers encompassing a team approach to therapy, including expertise in endocrinology, neurosurgery, and pathology. Individual surgical expertise is a major determinant of surgical outcomes and may be defined as a record of peer-reviewed publication of surgical results encompassing both endocrine and surgical evaluation and follow-up; training experience of more than 100 pituitary surgery cases, and annual surgical activity of more than 25 cases/surgeon. Specialized pituitary pathology is desirable, and immunostaining is mandatory for rigorous evaluation of surgical results. GH-secreting adenomas express somatostatin receptor forms; the SSTR2 receptor subtype appears to be a particularly important mediator for signals suppressing GH secretion (15). SRLs, administered by sc or im injection, effectively control GH axis biochemical parameters in 50–70% of patients (16–18) and provide sustained hormone suppression and alleviation of soft tissue manifestations of acromegaly as long as drug administration is continued (19). SRLs are recommended as the mainstay of medical therapy. Oral dopamine agonists are only effective in about 10% of patients, and in selected patients with coexistent hyperprolactinemia, dopamine agonists may be a preferable therapeutic choice, whereas combined use of SRL and dopamine agonist therapy may improve therapeutic efficacy (20). Long-acting depot SRL preparations and longer acting dopaminergic agents are preferred over the short-acting agents (21–24). The GH receptor antagonist (25) represents a novel approach for the treatment of acromegaly, particularly in somatostatin analog-resistant patients (26). Although the drug is investigational, and its long-term safety profile remains to be established, it will be especially useful for patients with persistently elevated IGF-I levels. Radiotherapy administered by conventional means (∼45–50 Gy total dose) is associated with relatively few adverse events other than hypopituitarism. Administered in fractionated doses not exceeding 1.75 Gy/session, radiotherapy can be considere
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Melmed, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmra062453 · Cited by 1,160
Self-citationCiric, I., Ragin, A., Baumgartner, C., & Pierce, D. (1997) · Neurosurgery · doi:10.1097/00006123-199702000-00001 · Cited by 1,029
Criteria for Cure of Acromegaly: A Consensus Statement
Giustina, A. (2000) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.2.526 · Cited by 987
Self-citationTreatment of Acromegaly with the Growth Hormone–Receptor Antagonist Pegvisomant
Trainer, P. J., Drake, W. M., Katznelson, L., Freda, P. U., Herman-Bonert, V., van der Lely, A. J., Dimaraki, E. V., Stewart, P. M., Friend, K. E., Vance, M. L., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200004203421604 · Cited by 879
Self-citationLong-Term Mortality after Transsphenoidal Surgery and Adjunctive Therapy for Acromegaly1
Swearingen, B., Barker, F. G., Katznelson, L., Biller, B. M. K., Grinspoon, S., Klibanski, A., Moayeri, N., Black, P. M., & Zervas, N. T. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.10.5222 · Cited by 586
Determinants of clinical outcome and survival in acromegaly
Rajasoorya, C., Holdaway, I. M., Wrightson, P., Scott, D. J., & Ibbertson, H. K. (1994) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1994.tb03789.x · Cited by 565
An audit of outcome of treatment in acromegaly
(1993) · QJM: An International Journal of Medicine · doi:10.1093/oxfordjournals.qjmed.a068816 · Cited by 466
Risk of second brain tumour after conservative surgery and radiotherapy for pituitary adenoma.
Brada, M., Ford, D., Ashley, S., Bliss, J. M., Crowley, S., Mason, M., Rajan, B., & Traish, D. (1992) · BMJ · doi:10.1136/bmj.304.6838.1343 · Cited by 413
Long-Term Mortality after Transsphenoidal Surgery and Adjunctive Therapy for Acromegaly
Swearingen, B. (1998) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.83.10.3419 · Cited by 400
Abosch, A., Tyrrell, J. B., Lamborn, K. R., Hannegan, L. T., Applebury, C. B., & Wilson, C. B. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.83.10.3411 · Cited by 361
Cited by
Acromegaly: An Endocrine Society Clinical Practice Guideline
Katznelson, L., Laws, E. R., Melmed, S., Molitch, M. E., Murad, M. H., Utz, A., & Wass, J. A. H. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-2700 · Cited by 1,786
Self-citationMelmed, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmra062453 · Cited by 1,160
Self-citationEffects of Growth Hormone on Glucose, Lipid, and Protein Metabolism in Human Subjects
Møller, N., & Jørgensen, J. O. L. (2009) · Endocrine Reviews · doi:10.1210/er.2008-0027 · Cited by 1,039
A Consensus on Criteria for Cure of Acromegaly
Giustina, A., Chanson, P., Bronstein, M. D., Klibanski, A., Lamberts, S., Casanueva, F. F., Trainer, P., Ghigo, E., Ho, K., & Melmed, S. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2670 · Cited by 783
Self-citationGuidelines for Acromegaly Management: An Update
Melmed, S., Colao, A., Barkan, A., Molitch, M., Grossman, A. B., Kleinberg, D., Clemmons, D., Chanson, P., Laws, E., Schlechte, J., et al. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-2421 · Cited by 764
Self-citationThe outcome of surgery in 668 patients with acromegaly using current criteria of biochemical ‘cure’
Nomikos, P., Buchfelder, M., & Fahlbusch, R. (2005) · European Journal of Endocrinology · doi:10.1530/eje.1.01863 · Cited by 500
Serum levels of insulin-like growth factor I and its binding proteins in health and disease
Juul, A. (2003) · Growth Hormone & IGF Research · doi:10.1016/s1096-6374(03)00038-8 · Cited by 467
Mortality in Patients with Pituitary Disease
Sherlock, M., Ayuk, J., Tomlinson, J. W., Toogood, A. A., Aragon-Alonso, A., Sheppard, M. C., Bates, A. S., & Stewart, P. M. (2010) · Endocrine Reviews · doi:10.1210/er.2009-0033 · Cited by 392
Clemmons, D. R. (2011) · Clinical Chemistry · doi:10.1373/clinchem.2010.150631 · Cited by 353
The epidemiology of pituitary adenomas in Iceland, 1955–2012: a nationwide population-based study
Agustsson, T. T., Baldvinsdottir, T., Jonasson, J. G., Olafsdottir, E., Steinthorsdottir, V., Sigurdsson, G., Thorsson, A. V., Carroll, P. V., Korbonits, M., & Benediktsson, R. (2015) · European Journal of Endocrinology · doi:10.1530/eje-15-0189 · Cited by 347
Ayuk, J., Clayton, R. N., Holder, G., Sheppard, M. C., Stewart, P. M., & Bates, A. S. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031584 · Cited by 343
Frystyk, J. (2004) · Growth Hormone & IGF Research · doi:10.1016/j.ghir.2004.06.001 · Cited by 338
A consensus on the diagnosis and treatment of acromegaly complications
Melmed, S., Casanueva, F. F., Klibanski, A., Bronstein, M. D., Chanson, P., Lamberts, S. W., Strasburger, C. J., Wass, J. A. H., & Giustina, A. (2013) · Pituitary · doi:10.1007/s11102-012-0420-x · Cited by 325
Self-citationOn behalf of The Pituitary Society, E. G. O. P. T., Casanueva, F. F., Barkan, A. L., Buchfelder, M., Klibanski, A., Laws, E. R., Loeffler, J. S., Melmed, S., Mortini, P., Wass, J., et al. (2017) · Pituitary · doi:10.1007/s11102-017-0838-2 · Cited by 315
Self-citationSheehan, J. P., Niranjan, A., Sheehan, J. M., Jane, J. A., Laws, E. R., Kondziolka, D., Flickinger, J., Landolt, A. M., Loeffler, J. S., & Lunsford, L. D. (2005) · Journal of Neurosurgery · doi:10.3171/jns.2005.102.4.0678 · Cited by 262
Self-citationPrevalence of Vertebral Fractures in Men with Acromegaly
Mazziotti, G., Bianchi, A., Bonadonna, S., Cimino, V., Patelli, I., Fusco, A., Pontecorvi, A., De Marinis, L., & Giustina, A. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0791 · Cited by 169
Self-citation
Metadata
- Authors
- Melmed, S., Casanueva, F. F., Cavagnini, F., Chanson, P., Frohman, L., Grossman, A., Ho, K., Kleinberg, D., Lamberts, S., Laws, E., Lombardi, G., Vance, M. L., Werder, K. V., Wass, J., & Giustina, A.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2002-09
- Volume
- 87
- Issue
- 9
- Pages
- 4054-4058
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2134378936
- Cited by
- 343
- References
- 39
- FWCI
- 15.76
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.